Clinical trial NCT06362642: A Study to Investigate the Effects of Itraconazole on the Pharmacokinetics of PC14586 in Healthy Participants
Official title: A Phase 1, Open-label, Fixed-sequence Study to Investigate the Effect of Coadministration of Itraconazole on the Pharmacokinetics of PC14586 in Healthy Participants
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy Volunteers
Keywords: Y220C
PC14586
PMV Pharma
PMV
itraconazole
rezatapopt
Phase 1
CYP3A4
Lead sponsor: PMV Pharmaceuticals, Inc
Sponsor class: INDUSTRY
First posted: 2024-04-12
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SEQUENTIAL
Intervention model description: The treatments will be: Day 1: single oral dose of PC14586, Day 20: oral dose of itraconazole BID, Day 21-22: single oral dose of itraconazole QD, Day 23: single oral dose of PC14586 and single oral dose of itraconazole, Day 24-27: single oral dose of itraconazole QD.
Primary purpose: OTHER

Brief summary: The purpose of this study is to assess the effect of PC14586 pharmacokinetics when co administered with itraconazole in healthy participants.

Detailed description: PC14586 is a first-in-class, oral, small molecule p53 reactivator that is selective for the TP53 Y220C mutation.

This is a Phase 1, open-label, fixed-sequence study to investigate the effect of coadministration of itraconazole on the pharmacokinetics (PK) of PC14586 (rezatapopt) in healthy male and female participants. Potential participants will be screened to assess their eligibility to enter the study within 56 days prior to the first dose administration. Participants will be admitted into the study site on Day -1 and be confined to the study site until discharge on Day 33. Participants will return to the study site for PK sample collection on Day 37 and a follow-up visit and PK sample collection on Day 42.

Approximately 16 participants will be enrolled in this study.

Eligibility criteria: Inclusion Criteria:

1. Healthy, non-smoking males and females, aged 18-55 years of age, with BMI between 18.0 and 32.0 kg/m2 inclusive.
2. In good health, determined by no clinically significant findings from medical history and evaluations at screening and check-in as assessed by the investigator.
3. Females of non-childbearing potential, males who agree to a highly effective method of contraception from first dose through 3 months after end of study visit.
4. Participants who are able to swallow tablets and capsules.
5. Participants who are capable and willing of giving signed informed consent.

Exclusion Criteria:

1. Participants with significant medical history or clinical manifestation of any medical condition, disease or disorder, as determined by the investigator.
2. History of significant hypersensitivity, intolerance, or allergy to itraconazole or any of the excipients or to medicinal products with similar chemical structures, food or other substance.
3. History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs.
4. Participant has blood pressure \>140 mmHg systolic or \>90 mmHg diastolic at screening or Day -1.
5. Prolonged QT interval corrected for heart rate using Fridericia's correction \>450 ms for males and \>470 ms for females at screening.
6. Positive hepatitis panel and/or positive human immunodeficiency virus test.
7. Abnormalities in liver function test ALT or AST \>1.5 × upper limit of normal.
8. Administration of any vaccine including coronavirus disease 2019 vaccine in the past 14 days prior to check-in.
9. Use or intend to use any medications/products known to alter drug absorption, metabolism, or elimination processes, including St. John's wort, within 30 days prior to check-in.
10. Use or intend to use any prescription medications/products or any nonprescription medications/products within 14 days prior to check-in.
11. Participation in a clinical study involving last administration of an investigational drug (new chemical entity) in the past 30 days prior to dosing, or within 5 half-lives of the IMP, whichever is longer, or have previously received PC14586.
12. Participant has a history of alcohol or drug/chemical abuse within 2 years prior to check-in and/or is unwilling to avoid use of caffeine or alcohol or caffeine-containing foods or alcohol-containing foods, medications, or beverages, within 48 hours prior to check-in until the follow up visit.
13. Use of tobacco- or nicotine-containing products (cigarettes, snuff, chewing tobacco, cigars, pipes, vaporizer, or nicotine-replacement products such as nicotine chewing gum and nicotine patches) within 3 months prior to check-in, or positive cotinine at screening or check-in.
14. Participants with a germline TP53 Y220C mutation at Screening.

Primary outcomes:
measure: Characterize the Maximum Plasma Concentration (Cmax) of PC14586 when co-administered with itraconazole in healthy participants.
timeFrame: 6 weeks
measure: Characterize the total drug exposure (AUC0-inf) of PC14586 when co-administered with itraconazole in healthy participants.
timeFrame: 6 weeks
measure: Characterize the time to peak drug concentration (Tmax) of PC14586 when co-administered with itraconazole in healthy participants.
timeFrame: 6 weeks
measure: Characterize the total drug exposure from time zero to 24 hours (AUC0-24) of PC14586 when co-administered with itraconazole in healthy participants.
timeFrame: 6 weeks
measure: Characterize the total drug exposure from time zero to the last timepoint (AUC0-t) of PC14586 when co-administered with itraconazole in healthy participants.
timeFrame: 6 weeks
measure: Characterize the half-life (t1/2) of PC14586 when co-administered with itraconazole in healthy participants.
timeFrame: 6 weeks
Secondary outcomes:
measure: Characterize the Maximum Plasma Concentration (Cmax) of PC14586 metabolites M13 and M14 when co-administered with itraconazole in healthy participants.
timeFrame: 6 weeks
measure: Characterize the total drug exposure (AUC0-inf) of PC14586 metabolites M13 and M14 when co-administered with itraconazole in healthy participants.
timeFrame: 6 weeks
measure: Characterize the time to peak drug concentration (Tmax) of PC14586 metabolites M13 and M14 when co-administered with itraconazole in healthy participants.
timeFrame: 6 weeks
measure: Characterize the total drug exposure from time zero to 24 hours (AUC0-24) of PC14586 metabolites M13 and M14 when co-administered with itraconazole in healthy participants.
timeFrame: 6 weeks
measure: Characterize the total drug exposure from time zero to the last timepoint (AUC0-t) of PC14586 metabolites M13 and M14 when co-administered with itraconazole in healthy participants.
timeFrame: 6 weeks
measure: Characterize the half-life (t1/2) of PC14586 metabolites M13 and M14 when co-administered with itraconazole in healthy participants.
timeFrame: 6 weeks
measure: Identification of the incidence of treatment emergent adverse events (TEAE) of PC14586 when administered alone and co-administered with itraconazole in healthy participants.
timeFrame: 6 weeks
measure: Identification of vital sign abnormalities after administration of PC14586 alone and when co-administered with itraconazole in healthy participants.
timeFrame: 6 weeks
measure: Identification of 12-lead electrocardiogram (ECG) abnormalities after administration of PC14586 alone and when co-administered with itraconazole in healthy participants.
timeFrame: 6 weeks
measure: Identification of laboratory abnormalities based on hematology and clinical chemistry after administration of PC14586 alone and when co-administered with itraconazole in healthy participants.
timeFrame: 6 weeks
Other outcomes:
Locations:
city: Madison
country: United States
facility: Fortrea
state: Wisconsin
Study officials:
References: